Exchange: NASDAQ Sector: Healthcare Industry: Health Information Services
Current Signal: SELL (auto-tracking)
2.78% $23.99
America/New_York / 26 apr 2024 @ 15:56
FUNDAMENTALS | |
---|---|
MarketCap: | 1 742.56 mill |
EPS: | 0.540 |
P/E: | 44.43 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 72.64 mill |
Avg Daily Volume: | 0.863 mill |
RATING 2024-04-26 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 44.43 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE 44.43 | industry: PE -4.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-22.62 (-194.31%) $-46.61 |
Date: 2024-04-26 |
Expected Trading Range (DAY) |
---|
$ 22.65 - 25.42 ( +/- 5.75%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Abel Robert Lorne | Buy | 30 000 | Stock Option (right to buy) |
2024-03-21 | Lorton Kenneth Patrick | Buy | 30 000 | Stock Option (right to buy) |
2024-03-06 | Lorton Kenneth Patrick | Buy | 5 574 | Common Stock |
2024-03-06 | Lorton Kenneth Patrick | Sell | 5 574 | Stock Option (right to buy) |
2024-03-04 | Porges Geoffrey Craig | Buy | 90 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
76.85 |
Last 97 transactions |
Buy: 2 214 027 | Sell: 335 407 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $23.99 (2.78% ) |
Volume | 0.548 mill |
Avg. Vol. | 0.863 mill |
% of Avg. Vol | 63.50 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $27.19 | N/A | Active |
---|
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.